Analysts Set Jazz Pharmaceuticals plc – (JAZZ) PT at $181.84

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) has received an average recommendation of “Buy” from the twenty-three research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating and seventeen have assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $181.84.

A number of analysts recently commented on JAZZ shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Sunday, December 3rd. Mizuho increased their price target on Jazz Pharmaceuticals from $144.00 to $150.00 and gave the company a “neutral” rating in a research report on Tuesday, December 5th. B. Riley reaffirmed a “buy” rating and set a $206.00 price target on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 5th. Wells Fargo reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Monday, December 25th. Finally, Zacks Investment Research downgraded Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd.

How to Become a New Pot Stock Millionaire

In other Jazz Pharmaceuticals news, CFO Matthew P. Young sold 700 shares of the firm’s stock in a transaction on Thursday, March 15th. The stock was sold at an average price of $151.22, for a total value of $105,854.00. Following the completion of the sale, the chief financial officer now directly owns 39,165 shares of the company’s stock, valued at $5,922,531.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction on Wednesday, March 14th. The stock was sold at an average price of $151.12, for a total value of $30,224.00. Following the completion of the sale, the executive vice president now directly owns 27,681 shares of the company’s stock, valued at $4,183,152.72. The disclosure for this sale can be found here. Insiders sold 12,758 shares of company stock valued at $1,881,171 over the last three months. Company insiders own 4.30% of the company’s stock.



Large investors have recently added to or reduced their stakes in the business. US Bancorp DE increased its position in Jazz Pharmaceuticals by 49.5% in the fourth quarter. US Bancorp DE now owns 1,087 shares of the specialty pharmaceutical company’s stock worth $147,000 after buying an additional 360 shares during the last quarter. We Are One Seven LLC bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth $157,000. Invictus RG bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth $206,000. Advisor Group Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 62.4% in the third quarter. Advisor Group Inc. now owns 1,431 shares of the specialty pharmaceutical company’s stock worth $210,000 after acquiring an additional 550 shares during the period. Finally, Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 795.4% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,746 shares of the specialty pharmaceutical company’s stock worth $255,000 after acquiring an additional 1,551 shares during the period. 91.20% of the stock is owned by institutional investors and hedge funds.

Shares of Jazz Pharmaceuticals stock traded down $4.66 on Monday, hitting $146.33. The company had a trading volume of 378,307 shares, compared to its average volume of 439,860. The company has a market cap of $9,029.72, a PE ratio of 15.31, a price-to-earnings-growth ratio of 0.79 and a beta of 0.97. Jazz Pharmaceuticals has a 1 year low of $128.58 and a 1 year high of $163.75. The company has a quick ratio of 3.15, a current ratio of 3.29 and a debt-to-equity ratio of 0.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 EPS for the quarter, missing the consensus estimate of $2.73 by ($0.15). The company had revenue of $436.40 million during the quarter, compared to analysts’ expectations of $440.91 million. Jazz Pharmaceuticals had a return on equity of 22.63% and a net margin of 30.14%. research analysts anticipate that Jazz Pharmaceuticals will post 11.48 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Analysts Set Jazz Pharmaceuticals plc – (JAZZ) PT at $181.84” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://stocknewstimes.com/2018/04/17/analysts-set-jazz-pharmaceuticals-plc-jazz-pt-at-181-84.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply